FDA clears CMS' I-Beam positioning system

CMS Inc. has received FDA 510(k) clearance for its I-Beam mobile patient positioning system that uses ultrasound and other images to locate target organs or tumors.

 I-Beam uses a 3D positioning technology with an integrated camera and free hand ultrasound probe that is registered through a passive localization target inserted in the shadow or wedge tray of a linear accelerator. This technology allows I-Beam to be self-contained without the need for hardware mounting in the treatment room.

 CMS is based in St. Louis, Mo., and develops and supports radiation treatment software. The company estimates that it has more than 1,400 treatment planning systems installed worldwide.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup